Araştırma Makalesi

İnterferon-gamma ile İndüklenebilir Protein-10: COVID-19 Hastalığı için Bir Ölüm Göstergesi Değildir

Cilt: 8 Sayı: 3 6 Eylül 2023
PDF İndir
EN TR

Interferon-Gamma Inducible Protein-10: Not a Mortality Marker for COVID-19 Disease

Abstract

Objective: Interferon-gamma inducible protein-10 (IP-10) released from macrophages is associated with thrombosis. We aimed to investigate patients' biochemical markers following severe COVID-19, concentrating on the role of IP-10 in mortality. Materials and Methods: In our study, we retrospectively evaluated data from 88 (females, 44.3%) severe patients followed in our university hospital's intensive care unit (ICU). We obtained demographic and laboratory data from our study population's files and electronic records, including D-dimer, ferritin, uric acid, IP-10 values, and other biochemical markers. Results: The mean age of all 88 patients with COVID-19 infection followed in the ICU was 70.5 ±10 years. The median for lymphocyte count was 1.3 (1-2.1) vs 0.8 (0.5-1.1) K/uL, ferritin 151 (90.7-255) vs 624 (296-1254) mcg/L, D-dimer 386 (293.5-650) vs 1280 (871-2245) ug/L, LDH 220 (185-286) vs 429.5 (368-560) U/L with a p-value of <0.05 in survivors vs non-survivors respectively. On the other hand, the level of IP-10 was 21.3 (13.2-31.6) vs 26.6 (11.4-43.6) pg/mL with a p-value of 0.04. Conclusions: In this study, in which non-survivors and survivors were compared in severe COVID-19 patients, it was found that ferritin and D-dimer were good predictors of mortality, while IP-10 could not be a predictor of mortality.

Keywords

Destekleyen Kurum

Sakarya University of Scientific Research Projects Unit

Proje Numarası

BAPK 2021-9-33-83

Teşekkür

We want to thank the Sakarya University of Scientific Research Projects Unit (Research Project number: BAPK 2021-9-33-83) for their financial support. Also, we would like to thank the company HUMANİS for their contribution and nonconditional support.

Kaynakça

  1. Chen Y, Wang J, Liu C, Su L, Zhang D, Fan J, et al. IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19. Mol Med. 2020;26(1):97. doi:10.1186/s10020-020-00230-x
  2. Clinical spectrum. COVID-19 Treatment Guidelines. https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/. Accessed May 19, 2023.
  3. Corominas H, Castellví I, Pomar V, Antonijoan R, Mur I, Matas L, et al. Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort. Clin Immunol. 2021;223:108631. doi:10.1016/j.clim.2020.108631
  4. Buszko M, Park JH, Verthelyi D, Sen R, Young HA, Rosenberg AS. The dynamic changes in cytokine responses in COVID-19: a snapshot of the current state of knowledge. Nat Immunol. 2020;21(10):1146-1151. doi:10.1038/s41590-020-0779-1
  5. Schultze JL, Aschenbrenner AC. COVID-19 and the human innate immune system. Cell. 2021;184(7):1671-1692. doi:10.1016/j.cell.2021.02.029
  6. Bignon E, Miclot T, Terenzi A, Barone G, Monari A. Structure of the 5’ untranslated region in SARS-CoV-2 genome and its specific recognition by innate immune system via the human oligoadenylate synthase 1. Chem Commun . 2022;58(13):2176-2179. doi:10.1039/d1cc07006a
  7. Lu Q, Zhu Z, Tan C, Zhou H, Hu Y, Shen G, et al. Changes of serum IL-10, IL-1β, IL-6, MCP-1, TNF-α, IP-10 and IL-4 in COVID-19 patients. Int J Clin Pract. 2021;75(9):e14462. doi:10.1111/ijcp.14462
  8. Sriram K, Insel PA. Inflammation and thrombosis in COVID-19 pathophysiology: proteinase-activated and purinergic receptors as drivers and candidate therapeutic targets. Physiol Rev. 2021;101(2):545-567. doi:10.1152/physrev.00035.2020

Ayrıntılar

Birincil Dil

İngilizce

Konular

Tıbbi Enfeksiyon Ajanları

Bölüm

Araştırma Makalesi

Erken Görünüm Tarihi

30 Ağustos 2023

Yayımlanma Tarihi

6 Eylül 2023

Gönderilme Tarihi

4 Nisan 2023

Kabul Tarihi

15 Temmuz 2023

Yayımlandığı Sayı

Yıl 1970 Cilt: 8 Sayı: 3

Kaynak Göster

AMA
1.İslam M, Dheir H, Özözen Şahin E, vd. Interferon-Gamma Inducible Protein-10: Not a Mortality Marker for COVID-19 Disease. OTSBD. 2023;8(3):363-368. doi:10.26453/otjhs.1276809

Creative Commons Lisansı
 

Online Türk Sağlık Bilimleri Dergisi Creative Commons Atıf-GayriTicari 4.0 Uluslararası Lisansı ile lisanslanmıştır.

Bu, Creative Commons Atıf Lisansı (CC BY-NC 4.0) şartları altında dağıtılan açık erişimli bir dergidir. Orijinal yazar(lar) veya lisans verenin adı ve bu dergideki orijinal yayının kabul görmüş akademik uygulamaya uygun olarak atıfta bulunulması koşuluyla, diğer forumlarda kullanılması, dağıtılması veya çoğaltılmasına izin verilir. Bu şartlara uymayan hiçbir kullanım, dağıtım veya çoğaltmaya izin verilmez.

Makale gönderme süreçleri ve "Telif Hakkı Devir Formu" hakkında yardım almak için tıklayınız.